Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Griffith

Showing results (61-70 of 115) with videos related to

Pageof 12
Sort By:
The European Respiratory Journal|April 20, 2019
Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasisEmily Henkle, Jeffrey R Curtis, Lang Chen, et al.
FEMS Immunology and Medical Microbiology|May 3, 2003
The CD14 receptor does not mediate entry of Mycobacterium tuberculosis into human mononuclear phagocytesHomayoun Shams, Benjamin Wizel, David L Lakey, et al.
Chest|February 13, 2015
Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung DiseaseJulie V Philley, Richard J Wallace, Jeana L Benwill, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 24, 2005
Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacteriumRamakrishna Vankayalapati, Ankita Garg, Angel Porgador, et al.
American Journal of Respiratory and Critical Care Medicine|June 13, 2015
Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung DiseaseDavid E Griffith, Jennifer Adjemian, Barbara A Brown-Elliott, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 17, 2021
Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung DiseaseChristopher M Rubino, Nikolas J Onufrak, Jakko van Ingen, et al.
Respiratory Medicine|September 29, 2020
Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimationJodie A Schildkraut, Jack Gallagher, Kozo Morimoto, et al.
Journal of Clinical Microbiology|August 16, 2013
In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolatesBarbara A Brown-Elliott, Elena Iakhiaeva, David E Griffith, et al.
European Journal of Drug Metabolism and Pharmacokinetics|April 19, 2021
Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung DiseaseChristopher M Rubino, Nikolas J Onufrak, Jakko van Ingen, et al.
Chest|August 28, 2020
Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians' Interpretation of a US Food and Drug Administration WorkshopPatrick A Flume, David E Griffith, James D Chalmers, et al.
Pageof 12

Showing results (61-70 of 115) with videos related to

Sort By:
Pageof 12
The European Respiratory Journal|April 20, 2019
Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasisEmily Henkle, Jeffrey R Curtis, Lang Chen, et al.
FEMS Immunology and Medical Microbiology|May 3, 2003
The CD14 receptor does not mediate entry of Mycobacterium tuberculosis into human mononuclear phagocytesHomayoun Shams, Benjamin Wizel, David L Lakey, et al.
Chest|February 13, 2015
Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung DiseaseJulie V Philley, Richard J Wallace, Jeana L Benwill, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 24, 2005
Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacteriumRamakrishna Vankayalapati, Ankita Garg, Angel Porgador, et al.
American Journal of Respiratory and Critical Care Medicine|June 13, 2015
Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung DiseaseDavid E Griffith, Jennifer Adjemian, Barbara A Brown-Elliott, et al.
European Journal of Drug Metabolism and Pharmacokinetics|February 17, 2021
Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung DiseaseChristopher M Rubino, Nikolas J Onufrak, Jakko van Ingen, et al.
Respiratory Medicine|September 29, 2020
Epidemiology of nontuberculous mycobacterial pulmonary disease in Europe and Japan by Delphi estimationJodie A Schildkraut, Jack Gallagher, Kozo Morimoto, et al.
Journal of Clinical Microbiology|August 16, 2013
In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolatesBarbara A Brown-Elliott, Elena Iakhiaeva, David E Griffith, et al.
European Journal of Drug Metabolism and Pharmacokinetics|April 19, 2021
Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung DiseaseChristopher M Rubino, Nikolas J Onufrak, Jakko van Ingen, et al.
Chest|August 28, 2020
Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians' Interpretation of a US Food and Drug Administration WorkshopPatrick A Flume, David E Griffith, James D Chalmers, et al.
Pageof 12